Conner Craigon
Impact in
- Hematology top 10%
- Multiple Myeloma Research and Treatments
- Oncology top 10%
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
Papers in
-
- Ubiquitin and proteasome pathways 9
- Protein Degradation and Inhibitors 9
- Histone Deacetylase Inhibitors Research 3
- Oncology 3
- Peptidase Inhibition and Analysis 2
- CAR-T cell therapy research 1
- Co-authors
- Alessio Ciulli (9 shared papers)Adam G. Bond (4 shared papers)Victoria G. Klein (1 shared paper)R. Scott Lokey (1 shared paper)Andrea Testa (2 shared papers)Kwok-Ho Chan (2 shared papers)Nikolai Makukhin (3 shared papers)Ryan Casement (1 shared paper)
- Journals
- Journal of Medicinal Chemistry (2 papers)Bioorganic & Medicinal Chemistry Letters (1 paper)Nature Chemical Biology (1 paper)Journal of the American Chemical Society (1 paper)ACS Medicinal Chemistry Letters (1 paper)
- Partner nations
- United KingdomUnited StatesAustria
In The Last Decade
Conner Craigon
9 papers receiving 503 citations
Peers
Comparison fields: 5 of 43
- Hematology 92
- Oncology 212
- Molecular Biology 483
- Organic Chemistry 35
- Virology 5
Countries citing papers authored by Conner Craigon
This map shows the geographic impact of Conner Craigon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Conner Craigon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Conner Craigon more than expected).
Fields of papers citing papers by Conner Craigon
This network shows the impact of papers produced by Conner Craigon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Conner Craigon. The network helps show where Conner Craigon may publish in the future.
Co-authors
The 25 scholars most cited alongside Conner Craigon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 181 | |
| 2 | 2021 | 103 | |
| 3 | 2021 | 66 | |
| 4 | 2021 | 60 | |
| 5 | 2024 | 35 | |
| 6 | 2022 | 34 | |
| 7 | 2024 | 19 | |
| 8 | 2025 | 12 | |
| 9 | 2025 | 1 |
About Conner Craigon
Conner Craigon is a scholar working on Molecular Biology, Oncology, Hematology, Infectious Diseases and Organic Chemistry, having authored 9 papers that have together received 511 indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (9 papers), Protein Degradation and Inhibitors (9 papers), Multiple Myeloma Research and Treatments (3 papers), Histone Deacetylase Inhibitors Research (3 papers), Peptidase Inhibition and Analysis (2 papers) and CAR-T cell therapy research (1 paper). The work is most often cited by research in Hematology (92 citations), Oncology (212 citations), Molecular Biology (483 citations), Organic Chemistry (35 citations) and Virology (5 citations). Conner Craigon has collaborated with scholars based in United Kingdom, United States and Austria. Frequent co-authors include Alessio Ciulli, Adam G. Bond, Victoria G. Klein, R. Scott Lokey, Andrea Testa, Kwok-Ho Chan, Nikolai Makukhin, Ryan Casement, Kristin M. Riching and Marjeta Urh. Their work appears in journals such as Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, Nature Chemical Biology, Journal of the American Chemical Society and ACS Medicinal Chemistry Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.